Sign Up
OverviewAPI
Biotech stocks, including Eli Lilly, Biogen, and Crispr, are expected to experience significant gains in 2024 due to multibillion-dollar deals, positive clinical results, and cutting-edge medical advancements. The sector is anticipated to rebound, driven by factors such as a more favorable interest-rate outlook, increased deal activity, and innovations in cancer and immunology. Analysts also predict a surge in M&A activity and improved investor risk appetite, making the biotech sector a stock picker's paradise.

Ask a question